# Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum

> **NCT04274166** · PHASE2 · WITHDRAWN · sponsor: **Wake Forest University Health Sciences**

## Conditions studied

- Pyoderma Gangrenosum

## Interventions

- **DRUG:** secukinumab 150 mg (2 injections per dose

## Key facts

- **NCT ID:** NCT04274166
- **Lead sponsor:** Wake Forest University Health Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-05
- **Primary completion:** 2021-12
- **Final completion:** 2022-04
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Contracting never completed, closed the IRB
- **Last updated:** 2021-05-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04274166

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04274166, "Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04274166. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*